NCT00049517 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia (NCT00049517)

Trial Description
Giving combination chemotherapy before a stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient’s immune system from rejecting the transplanted stem cells. When the healthy stem cells are infused into the patient they may help the patient’s bone marrow make stem cells, red blood cells, white blood cells, and platelets.

If the patient’s stem cells are to be transplanted, the patient is also treated with an antibody-drug conjugate such as gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), to kill any remaining cancer cells or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without gemtuzumab ozogamicin followed by stem cell transplant in treating acute myeloid leukemia.

This randomized phase III trial is studying combination chemotherapy, gemtuzumab ozogamicin, and stem cell transplant to see how well they work compared to combination chemotherapy and peripheral stem cell transplant alone in treating patients with acute myeloid leukemia.

This trial is sponsored by Eastern Oncology Group. [1]

Study Data

Study Schematic

(Coming soon)

Click here to Return to Drug map

Last Editorial review: July 22, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.